Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) issued its earnings results on Wednesday. Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%. Vanda Pharmaceuticals has a fifty-two week low of $4.14 and a fifty-two week high of $9.94. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Friday, July 17th. Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.Read MoreReceive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.